HSK 40118
Alternative Names: HSK-40118Latest Information Update: 06 Oct 2023
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action ErbB receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 04 Oct 2023 HSK 40118 is available for licensing as of 04 Oct 2023. https://en.haisco.com/Cooperator/
- 27 Mar 2023 Phase-I clinical trials in Non-small cell lung cancer (Metastatic disease, Inoperable/Unresectable, Late-stage disease) in China (PO) (NCT06050980)
- 10 Jan 2023 Preclinical trials in Non-small cell lung cancer in China (PO) prior to January 2023